The global Recombinant Vaccines Market, valued at USD 9.18 billion in 2022, is projected to experience remarkable growth, with forecasts indicating a surge to USD 21.46 billion by 2030. This growth trajectory represents a robust compound annual growth rate (CAGR) of 11.2% during the forecast period spanning from 2023 to 2030.Recombinant vaccines are a class of vaccines produced using recombinant DNA technology, where specific genes from a pathogen are inserted into a vector, such as a bacterium or yeast, to produce antigenic proteins that induce an immune response. These vaccines offer several advantages over traditional vaccine approaches, including improved safety, efficacy, and scalability.

Get a Sample PDF @ https://www.snsinsider.com/sample-request/3239 

Key players

Some major key players in the Recombinant Vaccines Market are Novartis AG, Merck & Co., Inc., Sanofi, Pfizer Inc, GC Biopharma, GSK pic., Bayer AG, Serum Institute of India Pvt. Ltd., Bharat Biotech, Sartorius AG and other players.

Key factors driving the growth of the Recombinant Vaccines Market include:

  1. Advancements in Biotechnology and Molecular Biology: Ongoing advancements in biotechnology, genetic engineering, and molecular biology techniques have facilitated the development of recombinant vaccine platforms, enabling the rapid and cost-effective production of vaccines against a wide range of infectious diseases.

  2. Increasing Focus on Vaccine Development and Immunization Programs: Growing investments in vaccine research and development, coupled with government-led immunization programs and public health initiatives aimed at preventing infectious diseases, are driving the demand for recombinant vaccines globally.

  3. Rising Incidence of Infectious Diseases: The rising incidence of infectious diseases, including COVID-19, influenza, hepatitis, and human papillomavirus (HPV), coupled with the emergence of new pathogens and viral variants, is fueling the demand for innovative vaccine technologies such as recombinant vaccines.

  4. Expanding Applications in Veterinary Vaccinology: Recombinant vaccine technology is also being increasingly utilized in veterinary vaccinology to develop vaccines for livestock, poultry, and companion animals, addressing the growing need for effective disease prevention in the agriculture and animal health sectors.

KEY MARKET SEGMENTS

By Indication

  • Meningococcal

  • Human Papillomavirus

  • Others

By End User

  • Adults

  • Pediatric

By Distribution Channel

  • Vaccination Centers

  • Hospitals

 

The forecast period of 2023-2030 is expected to witness continued research and development activities aimed at expanding the application of recombinant vaccine technology to address emerging infectious diseases, as well as to improve vaccine efficacy, stability, and delivery methods.

Geographically, North America currently dominates the Recombinant Vaccines Market, attributed to the presence of leading biotechnology companies, robust research infrastructure, and favorable regulatory environment. However, regions such as Europe, Asia Pacific, and Latin America are anticipated to witness significant growth opportunities during the forecast period, driven by increasing healthcare expenditure and rising demand for innovative vaccine solutions.

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Akash Anand – Head of Business Development & Strategy

info@snsinsider.com

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

Website: https://www.snsinsider.com